Prosight Management, LP Aurinia Pharmaceuticals Inc. Transaction History

Prosight Management, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	SELL	$10.93 - $23.55 $1.42 Million - $3.06 Million	-130,000 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$10.0 - $14.52 $2.31 Million - $3.35 Million	-230,834 Reduced 63.97%	130,000 $1.69 Million
Q1 2021 May 14, 2021	SELL	$12.3 - $18.73 $1.82 Million - $2.77 Million	-147,881 Reduced 29.07%	360,834 $4.69 Million
Q4 2020 Feb 12, 2021	SELL	$12.94 - $16.05 $1.12 Million - $1.38 Million	-86,285 Reduced 14.5%	508,715 $7.04 Million
Q3 2020 Nov 13, 2020	BUY	$13.19 - $16.66 $6.63 Million - $8.38 Million	503,000 Added 546.74%	595,000 $8.76 Million
Q2 2020 Aug 14, 2020	BUY	$14.12 - $18.33 $1.3 Million - $1.69 Million	92,000 New	92,000 $1.5 Million

207

58.6M

1.14M

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.27B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Prosight Management, LP, based on Form 13F filings with the SEC.

Stay updated on Prosight Management, LP with notifications on news.